-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Pipeline—creating tomorrow's vaccines today
The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our unique technology to address current and emerging threats.
Novavax continually conducts clinical trials and investigations and gathers real-world evidence to develop vaccines aimed at addressing public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of patients who take part in our trials.
Our pipeline
Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.
Our Matrix-M adjuvant technology

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.
Therapeutic area | Candidate | Technology | Phase of trial | Authorized use | |||
---|---|---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | ||||
Respiratory diseases COVID-19 | Novavax COVID-19 vaccine (NVX-CoV2373) | Matrix-M™ adjuvant | Authorized* | ||||
Respiratory diseases COVID-19 | Novavax COVID-19 Omicron vaccine | Matrix-M™ adjuvant | Phase 3 in progress | ||||
Respiratory diseases Seasonal influenza | Influenza (qNIV) vaccine | Matrix-M™ adjuvant | Phase 3 in progress | ||||
Respiratory diseases COVID-19 + seasonal influenza | COVID-influenza combination (CIC) vaccine | Matrix-M™ adjuvant | Phase 1/2 | ||||
Respiratory diseases Respiratory syncytial virus (RSV) | ResVax for infants via maternal immunization | Phase 3† in progress | |||||
Respiratory diseases Respiratory syncytial virus (RSV) | RSV F vaccine for children between 2-6 years old | Phase 1 | |||||
Respiratory diseases Respiratory syncytial virus (RSV) | RSV F vaccine for adults 60+ years old | Matrix-M™ adjuvant | Phase 1 | ||||
Respiratory diseases Middle East Respiratory Syndrome (MERS) | MERS vaccine | Preclinical | |||||
Respiratory diseases Severe Acute Respiratory Syndrome (SARS) | SARS vaccine | Preclinical | |||||
Parasitic diseases Malaria | R21‡ | Matrix-M™ adjuvant | Phase 2b in progress | ||||
Hemorrhagic diseases Ebola | Ebola GP vaccine | Matrix-M™ adjuvant | Phase 1 |
Respiratory diseases
COVID-19
Respiratory diseases
COVID-19
Respiratory diseases
Seasonal influenza
Respiratory diseases
COVID-19 + seasonal influenza
Respiratory diseases
Respiratory syncytial virus (RSV)
Respiratory diseases
Middle East Respiratory Syndrome (MERS)
Respiratory diseases
Severe Acute Respiratory Syndrome (SARS)
Parasitic diseases
Malaria
Hemorrhagic diseases
Ebola
*Authorized for use in several countries. For the full list of countries where we are authorized, please visit https://novavaxcovidvaccine.com.
†This trial did not meet its primary endpoint.
‡Investigational vaccine and trial sponsored by University of Oxford in collaboration with Serum Institute of India with Matrix-M adjuvant.
